Ranbaxy, Takeda Strike Licensing Deal Over Actos

Law360, New York (March 15, 2010, 1:45 PM EDT) -- Ranbaxy Laboratories Ltd. has agreed to license Takeda Pharmaceutical Co. Ltd.'s Actos patents in order to end a protracted legal battle and bring a generic version of the blockbuster diabetes treatment to market.

India-based Ranbaxy announced Monday that Takeda had agreed to drop its infringement action in the U.S. District Court for the Southern District of New York and grant Ranbaxy a nonexclusive royalty-free license to the seven U.S. patents covering Actos, the brand name for pioglitazone hydrochloride.

Under the terms of the deal, Ranbaxy is...
To view the full article, register now.